Biotech Values

[DewDiligence]

ABBV/ENTA—CHMP approves 8-week duration of Viekirax/Exviera* for treatment-naïve GT1b patients (except those with severe cirrhosis):

http://finance.yahoo.com/news/enanta-announces-chmp-grants-positive-110000679.html

When rubber stamped by the European Commission in a few months, the CHMP’s label expansion for Viekirax/Exviera should increase ABBV/ENTA’s market share in the EU, which is a predominantly GT1b market where Viekirax/Exviera already has a market share in the mid twenties (#msg-128526031).

However, the sales uplift for ABBV/ENTA from having an 8-week option for Viekirax/Exviera will be relatively short-lived insofar as ABBV/ENTA’s pan-genotypic G/P will be on the market in many EU countries within the next year or so (#msg-127281791), cannibalizing sales of Viekirax/Exviera.

*The EU brand name for Viekira Pak.